Ingredient

Ethylhexyl Methoxycinnamate

Ethylhexyl Methoxycinnamate is flagged for pregnancy, trying to conceive, breastfeeding, postpartum, PCOS and general use. The concern behind the strongest flag is endocrine disruptor and absorbed into the body.

By Team TruvaLast checked

Verdict by profile

Truva checks every ingredient against six profiles. Jump to any of them for the full assessment.

Strongest verdict
Not Recommended
Its verdict for pregnancy, the profile this one is worst in
Profiles flagged
6 of 6
Counting avoid, high risk and medium risk
Irritancy
0 of 5
Higher means more likely to sting or redden
PregnancyAVOID

Ethylhexyl Methoxycinnamate and pregnancy

Not Recommended

Ethylhexyl methoxycinnamate is a chemical UV filter that absorbs into the skin and enters the bloodstream at measurable levels. A 2019 FDA study found that after just one day of sunscreen application, octinoxate reached blood concentrations exceeding the FDA's safety threshold of 0.5 ng/mL, demonstrating significant systemic absorption. Animal studies have shown that octinoxate has estrogenic activity and can affect reproductive hormone levels and fetal development. While human pregnancy studies are limited, the combination of proven systemic absorption and endocrine-disrupting properties raises concerns during pregnancy, particularly in the first trimester when fetal hormone systems are developing. The American College of Obstetricians and Gynecologists (ACOG) recommends minimizing exposure to potential endocrine disruptors during pregnancy. Many dermatologists and obstetricians now recommend mineral sunscreens containing zinc oxide or titanium dioxide as safer alternatives during pregnancy, as these physical blockers remain on the skin surface rather than being absorbed. While octinoxate is not absolutely prohibited, the precautionary principle suggests choosing better-studied alternatives given the available evidence of hormonal effects and systemic absorption.

BreastfeedingCAUTION

Ethylhexyl Methoxycinnamate and breastfeeding

Caution Advised

Octinoxate is readily absorbed through the skin into the bloodstream, with peak blood levels occurring within hours of application. As a lipophilic (fat-soluble) compound, it has the potential to accumulate in fatty tissues and theoretically transfer to breast milk, though specific studies measuring octinoxate in human breast milk are limited. Given its demonstrated endocrine-disrupting properties and systemic absorption, many pediatricians and dermatologists suggest caution with octinoxate during breastfeeding. While there's no definitive evidence of harm to breastfed infants, the precautionary approach is to minimize infant exposure to hormone-disrupting chemicals when safer alternatives exist. Mineral sunscreens with zinc oxide or titanium dioxide are recommended as safer alternatives during breastfeeding, as they provide effective sun protection without systemic absorption. If using products with octinoxate, avoid applying them on or near the breast area to prevent direct infant contact.

PostpartumCAUTION

Ethylhexyl Methoxycinnamate and postpartum

Caution Advised

For postpartum women not breastfeeding, the concerns with octinoxate relate to its general endocrine-disrupting potential and systemic absorption rather than pregnancy-specific risks. The hormonal fluctuations during the postpartum period may make some women prefer to avoid additional endocrine disruptors. If sun protection is needed, mineral sunscreens or newer-generation chemical filters with better safety profiles offer effective alternatives. However, using octinoxate during the postpartum period (when not breastfeeding) carries the same risks as for the general population rather than elevated pregnancy-related concerns.

Trying to ConceiveAVOID

Ethylhexyl Methoxycinnamate and trying to conceive

Not Recommended

When trying to conceive, minimizing exposure to endocrine disruptors is recommended by reproductive endocrinologists. Octinoxate's estrogenic activity could theoretically interfere with the hormonal balance necessary for ovulation and conception, though direct human fertility studies are lacking. The systemic absorption of octinoxate and its documented hormonal effects suggest it's prudent to switch to mineral sunscreens or hormone-neutral alternatives when actively trying to conceive. This precautionary approach is particularly important during the preconception period when optimizing hormone function supports fertility and prepares the body for pregnancy.

PCOSCAUTION

Ethylhexyl Methoxycinnamate and PCOS

Caution Advised

Women with PCOS already experience hormonal imbalances, particularly elevated androgens and often insulin resistance. Octinoxate has demonstrated estrogenic activity in studies, meaning it can mimic or interfere with estrogen signaling in the body. This hormonal interference could theoretically affect the delicate hormone balance women with PCOS are working to regulate. While there are no specific studies on octinoxate's effects in women with PCOS, the precautionary principle suggests that women managing hormonal conditions may benefit from avoiding known endocrine disruptors. This is particularly relevant for those using hormonal treatments like birth control pills or anti-androgens to manage PCOS symptoms. Mineral sunscreens (zinc oxide, titanium dioxide) or newer chemical filters without hormonal activity provide effective sun protection without endocrine concerns. Since sun protection is important for preventing melasma and hyperpigmentation (common in PCOS), choosing hormone-neutral alternatives is advisable.

General UseCAUTION

Ethylhexyl Methoxycinnamate and general use

Caution Advised

Ethylhexyl methoxycinnamate is one of the most widely used UV filters globally, effective at absorbing UVB radiation to prevent sunburn and skin damage. It's found in sunscreens, moisturizers, makeup, and lip products with SPF. It works by absorbing UV light and converting it to heat. The FDA's 2019 and 2020 studies demonstrated that octinoxate achieves blood concentrations above 0.5 ng/mL (the threshold requiring further safety evaluation) after typical sunscreen use. Multiple studies have shown endocrine-disrupting potential, with estrogenic activity demonstrated in cell cultures and animal models. Research has also detected octinoxate in urine samples, confirming systemic exposure. While these findings don't prove harm in humans at typical exposure levels, they raise questions about long-term daily use. The ingredient remains approved in the US (though under FDA review) and EU (up to 10% concentration), but several jurisdictions have banned it due to environmental concerns about coral reef damage. Consumers increasingly prefer mineral alternatives or newer-generation organic filters like Tinosorb or Mexoryl that lack hormonal activity. For those continuing to use octinoxate, applying it to limited body areas rather than full-body daily may reduce total exposure.

Same profiles

Everything else flagged for the same profiles

Keep reading

Related ingredients

Ingredients suggested in place of Ethylhexyl Methoxycinnamate, each one with its own page here.

Ingredients that raise the same concerns.

Provenance

Where this came from

Truva summarises published guidance from bodies including ACOG, the FDA, the EU SCCS and the Cosmetic Ingredient Review. It has no access to your medical history and it is not a substitute for your doctor, dermatologist or midwife. These assessments have not been reviewed by a clinician, and nothing here is a diagnosis or a prescription. If you are pregnant, breastfeeding or being treated for PCOS, take the ingredient list to the person looking after you.

Assessment last pulled from the ingredient database on .

One ingredient is the easy case.

A label has thirty of them. Truva reads the whole list at once and answers for the profile you set: pregnancy, breastfeeding, postpartum, trying to conceive, PCOS, or general use.

Download on theApp Store